Cover Image
市場調查報告書

轉移性移形細胞癌症(泌尿道轉移性細胞癌):全球臨床實驗檢討

Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014

出版商 GlobalData 商品編碼 299730
出版日期 內容資訊 英文 121 Pages
訂單完成後即時交付
價格
Back to Top
轉移性移形細胞癌症(泌尿道轉移性細胞癌):全球臨床實驗檢討 Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014
出版日期: 2014年04月15日 內容資訊: 英文 121 Pages
簡介

本報告提供轉移性移形細胞癌症(泌尿道轉移性細胞癌)相關的臨床研究最新趨勢分析,提供疾病·治療方法概要,及主要已開發國家·新興國家的臨床實驗狀況,各地區、各階段、Phase別的進行狀況,彙整有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊,為您概述為以下內容。

目錄

簡介

  • 轉移性移形細胞癌症(泌尿道轉移性細胞癌)
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區前五名國家的臨床實驗數量
    • 歐洲前五名國家的臨床實驗數量
    • 北美的主要國家的臨床實驗數量
    • 中東·非洲的主要國家的臨床實驗數量
    • 中南美的主要國家的臨床實驗數量

在G7各國臨床實驗數量:佔腫瘤整體比率

在G7各國臨床實驗數量:各階段(Phase別)

在G7各國臨床實驗數量:各進展狀況

在E7各國臨床實驗數量:佔腫瘤整體比率

各階段(Phase別)臨床實驗數量

  • 進行中的臨床實驗:Phase別

各進展狀況臨床實驗數量

臨床實驗的目標的成就情形

未完成的臨床實驗數量

一定期間所採用的實驗對象

贊助商的不同種類的臨床實驗數量

有潛力的贊助商

  • 參加轉移性移形細胞癌症(泌尿道轉移性細胞癌)治療藥臨床實驗的前幾名企業

有潛力的藥劑

臨床實驗簡介

  • 代表性企業臨床實驗概要
    • F. Hoffmann-La Roche Ltd.
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company
    • AstraZeneca PLC
    • Eisai Co., Ltd.
    • Boehringer Ingelheim GmbH
    • Biotest AG
    • Astellas Pharma Inc.
    • Altor BioScience Corporation
  • 有代表性的研究機關·醫院臨床實驗概要
    • National Cancer Institute
    • The University of Chicago
    • European Organization for Research and Treatment of Cancer
    • Icahn School of Medicine at Mount Sinai
    • Memorial Sloan Kettering Cancer Center
    • Barts and The London NHS Trust
    • The Wales Cancer Trials Unit
    • Northern California Cancer Center
    • The University of Texas M. D. Anderson Cancer Center

5個有代表性的臨床實驗簡介

附錄

圖表一覽

目錄
Product Code: GDHC2077CTIDB

GlobalData's clinical trial report, "Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer)
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Metastatic Transitional Cell Cancer (Urothelial Cell Cancer)
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials
  • Prominent Drugs
    • Clinical Trial Profiles
      • Clinical Trial Overview of Top Companies
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
      • Eli Lilly and Company
      • Clinical Trial Overview of Eli Lilly and Company
      • Bristol-Myers Squibb Company
      • Clinical Trial Overview of Bristol-Myers Squibb Company
      • AstraZeneca PLC
      • Clinical Trial Overview of AstraZeneca PLC
      • Eisai Co., Ltd.
      • Clinical Trial Overview of Eisai Co., Ltd.
      • Boehringer Ingelheim GmbH
      • Clinical Trial Overview of Boehringer Ingelheim GmbH
      • Biotest AG
      • Clinical Trial Overview of Biotest AG
      • Astellas Pharma Inc.
      • Clinical Trial Overview of Astellas Pharma Inc.
      • Altor BioScience Corporation
      • Clinical Trial Overview of Altor BioScience Corporation
    • Clinical Trial Overview of Top Institutes / Government
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
      • The University of Chicago
      • Clinical Trial Overview of The University of Chicago
      • European Organization for Research and Treatment of Cancer
      • Clinical Trial Overview of European Organization for Research and Treatment of Cancer
      • Icahn School of Medicine at Mount Sinai
      • Clinical Trial Overview of Icahn School of Medicine at Mount Sinai
      • Memorial Sloan Kettering Cancer Center
      • Clinical Trial Overview of Memorial Sloan Kettering Cancer Center
      • Barts and The London NHS Trust
      • Clinical Trial Overview of Barts and The London NHS Trust
      • The Wales Cancer Trials Unit
      • Clinical Trial Overview of The Wales Cancer Trials Unit
      • Northern California Cancer Center
      • Clinical Trial Overview of Northern California Cancer Center
      • The University of Texas M. D. Anderson Cancer Center
      • Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Region, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
  • Proportion of Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Eisai Co., Ltd., 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Boehringer Ingelheim GmbH, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Biotest AG, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Altor BioScience Corporation, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Chicago, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Icahn School of Medicine at Mount Sinai, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Barts and The London NHS Trust, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by The Wales Cancer Trials Unit, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Northern California Cancer Center, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014*

List of Figures

  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014*
  • Proportion of Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top